

Preparation of EUTCD-Grade Human Embryonic Cell Lines for use as Starting Materials for the **Development of Clinical Therapies**

J Man¹, H Taylor¹, M Barbato¹, S Spryou¹, C Hunt¹ and G Stacey¹

¹UK Stem Cell Bank, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom, EN6 3QG

Overview of the Cell Banking Process Quality Control Testing Due Diligence review of depositor's cells to ensure compliance with HTA The UK Stem Cell Bank (UKSCB) is a key component of the UK All cell lines are QC tested at the following time points: regenerative medicine infrastructure charged with procuring, Upon thaw \Rightarrow Receipt of depositor's processing (banking and testing) and distributing seed stocks of cells (2-6 vials/straws and quarantine In-process/during expansion \Rightarrow human embryonic stem cell (hESC) lines for research and human Accessioning of Expansion Prior to banking application. \Rightarrow depositor's cells . E.g. C-16-001 Subculture After cryopreservation/post-recovery One of the key objectives of the UKSCB is to bank and release a \Rightarrow Cryopreservati panel of carefully selected stem cell lines that meet the EU Tissue Expansior Pre-Master Cell Bank and Cell Directives (EUTCD) as set out in Human Tissue Authority (PMCB) (6-12 vials) Subculture Example mandatory release test reports (L-R): STR profile; G-(HTA) regulations which set a benchmark for the standards that Cryopreservati banding karyology result; mycoplasma culture report. must be met when carrying out any activity involving tissues and Expansion Α. ster Cell Bank (MCB) cells for human application. (20-50 vials ryopreservati Distribution Cell Bank (DCB) (50-100 vials) testing Cell line master file Release of cell line **Due Diligence, Receipt and Accessioning Due Diligence Process** B All cells are subject to ethical scrutiny by a national Steering Committee, following which the UKSCB performs a 24h EB Day 0 EB Day 7 EB due diligence protocol which establishes for each individual cell line, whether it could meet the requirements of the EUTCD and is thereby provide a starting material for clinical trials. Receipt of the Cell Line at the UKSCB

Cell sample integrity and depositor's documentation are checked upon receipt at the UKSCB to ensure the

information matches the cells received.


Allocation of Accession Number


The cell line is given an accession number which is a unique identifier used to track cells through the production process and is linked to the UK Steering Committee deposit reference number to ensure traceability. A unique Single European Code, Donation Identification Sequence is also allocated to each cell line as required in the EU.

Cell Storage

Following receipt and accessioning, EUTCD-grade cell lines are stored in a quarantine vessel prior to processing.







Example informational test results: Photomicrographs of typical cell morphology of hESCs cultured on iHDFs (A). Photomicrographs of embryoid bodies formed from hESCs to assess differentiation capacity (B). qPCR analysis of embryoid bodies to assess differentiation potential into the three germ layers (endoderm, mesoderm and ectoderm (C). Flow cytometry analysis to check for "stemness" markers (D).

Cell Bank Release Procedure

- 1) The Cell Line Master File (CLMF) is firstly completed and reviewed:
 - The CLMF contains all information related to the cell line including traceability, production and QC \Rightarrow documentation.
 - It is reviewed by UKSCB production, NIBSC Quality department and the Bank's designated individual prior to release of the cell line for distribution.
 - Ultimately, it will feed into the Cell Line History File which will attribute to future Product Dossiers for regulatory review of stem cell-derived cellular therapies.

2) Cell banks which "pass" QC release tests can then be moved to the "Release" LN₂ storage vessel .

3) The UKSCB on-line catalogue is updated to show that the cell line is "available" along with sex determination and any HLA data.

4) Distribution of EUTCD-grade human embryonic stem cells will be accompanied by a Certificate of Analysis (see example below) and UKSCB protocols to assist with cell recovery.

Bio


NIBSC		ficate of		UK Stem Cell Ba	
	An	alysis			
Cell Line Name: Celline1	.23	Depositor: Cel	Supply1	23	
UKSCB Accession No.: C-16-000	Cell Type: Human embryonic stem cell	Grade: EUTCD Grade:		Laboratory Grade: 🔲	
UKSC Reference No.: SCSC00-00 Intended Use:	hESCReg ID No.	Original Publication Reference: PubMed ID 🛛 n/a			
These cells may be used for Cl	linical StartingMaterials	These cells are r	not for N/a	a No restrictions apply	
Date Embryo Produced:	01/01/15 🔲 n/a	Date Cell Line [Derived:	01/03/15	
Date Cell Bank Cryopres 01/12/16	01,	ank Released: /03/17	30 yea	Expiry Date: rs from date of cryopreservation	
Bank Type: Distribution	Bank ID No. D01	Passage No.: P15		Cell Number / Vial: Nominal 1 x 10 ⁶	
Feeder Dependent:		Feeder Indepe	ndent:		
Feeder Cell Line: Human	(HDFn)	Culture Matrix	Choos	e an item.	
Recommended Culture/Storage Conditions	should be incubated a	at 37°C and 5% CO2 inically and/ or with oling rate of 1°C/m	concen h a disso hinute an	em media was used. Cultur tration. The cell line can be ciation reagent. Cells are id stored at -196°C* culture manuals for detailed informa	
	At 37°C for 5 mins and into 1 well of a 6-wel plate			1:6 every 6 days	
	into 1 well of a 6-wel plate	Ratios for Estal		1:6 every 6 days	
Celline123 P15 prior	into 1 well of a 6-well plate Cultu	Ratios for Estal Cultures	blished	1:b every b days	

National Institute for Biological Standards and Con

<u>%۱</u>	NIBSC		Certificate of Analysis			UK Stem Cell Bank			
ological	Safety								
	Test		Assay Acceptance Criteria		Result				
Sterility			Bacter	ia/fungi	Not detected	Pass Not Tested		Not Tested	
ycoplasma	3		Culture	6	Not detected	\boxtimes	Pass		Not Tested
ycoplasma	8		PCR		Not detected	\boxtimes	Pass		Not Tested
	Hepatitis B		PCR		Not Detected	\boxtimes	Pass		Not Tested
H	Hepatitis C	lepatitis C			Not Detected	\boxtimes	Pass		Not Tested
	HIV-1		PCR		Not Detected	\boxtimes	Pass		Not Tested
rus Panel	anel HIV-2 HTLV-1 Epstein Barr virus (EBV) Human Cytomegalovirus CMV)		PCR		Not Detected	\boxtimes	Pass		Not Tested
			PCR		Not Detected	\boxtimes	Pass		Not Tested
			PCR		Not Detected	\boxtimes	Pass		Not Tested
			PCR		Not Detected	\boxtimes	Pass		Not Tested
ability	and Identit	y*		Yor copie	of the Cell Line Identity Test result to	entect the UKS	Ka (masina	a@ulatame	elbank.og)
	Test Assay		Acceptance Criteria		Result				
ability embrane	dye exclusion)	Trypan Blue		270% dye excluding cells prior to freezing		\boxtimes	Pass		Not Tested
I Recover	у	Recovery and expansion		Recovery of cells on thawing			Pass		Not Tested

Production

Cell Culture and Storage



- EUTCD-grade cell lines may be banked in one continuous process but may also comprise discrete production runs.
- A cell line is grown under conditions using standard operating procedures (SOPs) taken from the depositor's protocols (UKSCB Cell Line Information Form) or from validated in-house UKSCB SOPs.
- During production, records are completed and signed by the operator and reviewed by the Production Manager and Quality Assurance (QA).
- All EUTCD-grade cell lines are:
- \Rightarrow Grown in serum-free, serum replacement, or xeno-free media with a formal risk assessment process applied to all critical reagents.
- Co-cultured on inactivated human feeders (iHDF) or on synthetic matrices prior to banking. \Rightarrow
- Passaged mechanically or by using dissociation reagents. \Rightarrow
- Banked using a controlled rate cooling method in cryogenic vials. \Rightarrow
- Placed into a dedicated "in-process" liquid nitrogen (LN₂) storage vessel until Quality Control (QC) testing \Rightarrow is complete.
- \Rightarrow The majority of frozen vials are stored at the UKSCB but a number of vials are also stored in a HTA compliant off-site storage facility under a disaster recovery plan.

Quality Control Testing

QC tests are based on Good Cell Culture Practice (under revision), EU Tissue and Cells Directive (2004) and The ISCBI **Consensus Guidance Document** (2015).

The UKSCB employ mandatory and information QC tests (Table 1) for the release of a cell line that there is ensuring consistency between each cell bank and with the Depositor's material.

Mandatory Release QC test	Method
Viability	Trypan Blue Exclusion assay and NC3000
Sterility and in-process finger dabs and settle plates	Sterility: Cell supernatant incubated in Tryptone soya broth, Fluid thioglycollate medium and Sabaroid's liquid medium for 14 days; Finger dabs and settle plates are taken at the thawing and cryopreservation stages
Mycoplasma	EU Pharmacopeial broth/culture test and Mycoplasma/ Ureaplasma PCR
Viral PCR	DNA extract tested against a panel of human ∨iruses: hCMV, HTLV1, HIV1, HIV2, HepB, HepC, EBV
DNA profiling	Applied Biosystems AmpF/STR Identifier kit
Informational test	Method
G-band karyotyping	Giemsa staining of metaphase chromosomes
"Stemness" markers	Flow cytometric analysis using the following panel of anti- bodies: Tra-1-60, Oct4, Nanog, and SSEA-1.
Differentiation	Embryoid body Q-PCR analysis of 13 self-renewal/ differen- tiation genes

			materials	upplied by Dep	ositor					
Informationa	al Tests*		*for cop	ies of Informational	Test results con	tect the UKSCS	(enquiries@uks	ta mcallbank.og)		
Test		Assay			Result					
Morphology	Visual assess	Visual assessment/photographic record			Typical colonial morphology with low level of differentiation					
Karyotype	G-Banding			Normal human karyotype 45 XX						
a		Expression of SSEA-1		Low	Inter	mediate	🔲 High	Not Tester		
		Expression of TRA-1-60		Low	Inter	mediate	🛛 High	Not Tester		
		Expression of Oct 4		Low	🛛 Inter	mediate	🗌 High	Not Tester		
Phenotype	Flow	Expression of Nanog		Low	🛛 Inter	mediate	🗌 High	Not Tester		
Phenotype	cytometry	Expression of Sox 2		Low	Inter	mediate	🗌 High	Not Tester		
		Expression of SSE/	4-4	Low	Inter	mediate	🗌 High	Not Tester		
		For all "stemness" markers: Law <30%; intermediate 30 – 60%; High >60% For SSEA-1: Law <10%; Intermediate 10 – 30%; High >30%								
Differentiation Potential	Differentiation and qPCR for tri-lineage markers			Upregulation of germ layer markers detected for the following: Endoderm: Detected Mesoderm: Detected Ectoderm: Detected						
HLA	Information	supplied by the Depo	sitor	LABType SSO (A, B, C, DRB1, DQA1 & DQB1)						
	es of Analysis are based on	accordance with the requirement in Information contained in the Cal re and skill in its compliation, prep	Line Master File. Q	C testing indicates that t	he material supple		cification for release.	Information emanating from		
NISC is given after the exa- in humans (that is EUTCO- Rests actuated from the put the use of this product, whe lability whatsoever for: (i) condition of newlight of a negl Release by:	roduct are likely to be dep ther loss of profits, or indi- neaults obtained from this acement product, accepts	Is the responsibility of the user to pendent on conditions of use and next or consequential loss or othe is product; and/or (II) non-delivery ance of the fact that the replaceme	the variability of mat nulae, including, but r of goods or for dam with not to be constru-	as the necessary technic while it beyond the cont not limited to, personal it ages in transit. In the used as an admission of its	al skills to determine rol of NISSC, NISS tjury other than as event of any replace	and use. Where the appropriates a the appropriates accepts no fabilit caused by the neg ement of goods for half.	heat of this product if by whatspever for an pigence of NIBSC In	for the proposed application, y loss or damage arising from particular, NI BSC accepts no ge a customer accepts as a		
NIESC is given after the exe in humane (that is EUTCO- Results obtained from this product, wh the use of this product, wh fability whatspever for: (2) condition of receipt of a repl	roduct are likely to be dep other loss of profits, or indi results obtained from this	pendent on conditions of use and inect or consequential loss or othe is product; and/or (I) non-delivery	the variability of mat nulae, including, but r of goods or for dam with not to be constru-	as the necessary technic erisis is beyond the cont not limited to, personal is ages in transit. In the c	al skills to determine rol of NISSC, NISS tjury other than as event of any replace	and use. Where the appropriates a the appropriates accepts no fabilit caused by the neg ement of goods for half.	near of this product f by whatsoever for an gigence of NIBSC. In plowing loar or dema	for the proposed application, y loss or damage arising from particular, NI BSC accepts no ge a customer accepts as a		
NISC glas she the the us in human (that is DUTC)- faults stabilist to DUTC)- faults stabilist to DUTC)- faults of this product, while the use of this product is not condition of newlys of a not Release by: UKSCS Production Approved by:	roduct are likely to be dep ther load of profile, or indi- mealts obtained from this accement product, accepts Signature	pendent on conditions of use and inect or consequential loss or othe is product; and/or (I) non-delivery	the variability of math nules, including, but i of goods or for dam with not to be constru- plin	as the necessary technic while it beyond the con- not inhest to, personal is ages in transit. In the used as an admission of its of Name	al skills to determine rol of NISSC, NISS tjury other than as event of any replace	and us. Where is a the appropriate accepts no liability caused by the neg ement of goods for half.	near of this product f by whatsoever for an gigence of NIBSC. In plowing loar or dema	for the proposed application, v load or damage adding from, particular, NBCS accepts and ge a cultomer accepts as a		
NIECE is plan after the exe in humans (that is DUTCO- Result abstand from the put the use of this product, whe facility whereaver for (i) condition of receipt of a real Release by: UKSCS Production	roduct are likely to be dep ther loss of profits, or indi- neaults obtained from this acement product, accepts	pendent on conditions of use and inect or consequential loss or othe is product; and/or (I) non-delivery	the variability of math nules, including, but i of goods or for dam with not to be constru- plin	as the necessary technic while it beyond the cont not limited to, personal it ages in transit. In the used as an admission of its	al skills to determine rol of NISSC, NISS tjury other than as event of any replace	and us. Where is a the appropriate accepts no liability caused by the neg ement of goods for half.	near of this product (ty whatsoever for an gigence of NI BSC. In Slowing loas or dema	for the proposed application, v load or damage adding from, particular, NBCS accepts and ge a cultomer accepts as a		
NISC glas she the the us in human (that is DUTC)- faults stabilist to DUTC)- faults stabilist to DUTC)- faults of this product, while the use of this product is not condition of newlys of a not Release by: UKSCS Production Approved by:	oduct ne linely to be deg enter loss of profes, or hol multa obstated from this sciences product, accepts Signature Signature	pendent on conditions of use and inter or consequential loss or other a product, and/or (0) non-delivery ance of the fact that the replacement on a of the fact that the replacement	the variability of math nules, including, but i of goods or for dam with not to be constru- plin	as the necessary technic while it beyond the con- not inhest to, personal is ages in transit. In the used as an admission of its of Name	al skills to determine rol of NISSC, NISS tjury other than as event of any replace	ind use When it is the approximation of both caused by the real second by the real	nes of the product y unbacever for an glgence of NI BSC. In glgence of NI BSC in should gloss or dama	for the proposed application, v load or damage adding from, particular, NBCS accepts and ge a cultomer accepts as a		

DNA profile consistent with

Details of banking progress and HLA type available upon request. http://www.nibsc.org/

Acknowledgements

Medical Research Council, National Institute for Biological Standards and Control and the Biotechnology and **Biological Sciences Research Council.**





